Sanofi Pasteur's India Arm Shantha Biotech Bags WHO Supply Contract For Pentavalent Vaccines
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Shantha Biotechnics - the Indian biotech acquired by Sanofi-Aventis - has bagged a $340 million contract from the World Health Organization for supply of the pentavalent vaccine branded SHAN5 over a period of two years starting 2010. The vaccine indigenously developed by Shantha immunizes children against diphtheria, pertussis, tetanus, hemophillus influenza B and hepatitis B
You may also be interested in...
India Tightens Income Tax Noose On Sanofi-Aventis' Shantha Biotech Deal
India's tax authority claims it is owed for capital gains on the deal between two French companies because it was an Indian company that changed hands.
India Tightens Income Tax Noose On Sanofi-Aventis' Shantha Biotech Deal
India's tax authority claims it is owed for capital gains on the deal between two French companies because it was an Indian company that changed hands.
WHO Does What It Warned: Delists Shantha Biotech's Pentavalent Vaccine Shan5; More Pains For Sanofi-Aventis?
MUMBAI - In a move that could in the short term severely impair the reputation of Hyderabad-based vaccines maker Shantha Biotechnics, now part of Sanofi-Aventis, the World Health Organization has delisted its popular pentavalent vaccine Shan5, which is used by scores of nations as part of their national immunization programs for the prevention against deadly diseases like diphtheria, tetanus, hepatitis B and Hib